Toxicological characteristics of the drug Hyperico

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The article presents the results of a study of the toxicity of the drug Hyperico. It has been established that the drug is low-toxic and safe for animals with daily use. It does not provoke the development of pathological reactions. According to the classification of Hodge and Sterner (1943), Hyperico can be classified as toxicity class 6 – relatively harmless. The LD50 value of the drug after intragastric administration to white rats was ≥ 36400 mg/kg, to mice – ≥ 45400 mg/kg, irritation of the mucous membranes of the digestive tract was not observed. According to GOST 12.1.007.76, Hyperico belongs to the 4th hazard rating, that is low-hazard substances. Based on the results of the study, a reasonable conclusion can be made that Hyperico does not have a toxic effect on calves. There are no contraindications for conducting clinical trials of the drug Hyperico.

Full Text

Restricted Access

About the authors

O. D. Sklyarov

Federal State Institution “The Russian State Center for Quality and Standardization of Animal Drugs and Feed”

Author for correspondence.
Email: scliarov@yandex.ru

Grand PhD in Veterinary Sciences

Russian Federation, Moscow

E. K. Rakhmatullin

Federal State Budgetary Scientific Institution Federal Center for Toxicological, Radiation and Biological Safety”

Email: scliarov@yandex.ru

Grand PhD in Veterinary Sciences

Russian Federation, Kazan

O. V. Babicheva

Federal State Institution “The Russian State Center for Quality and Standardization of Animal Drugs and Feed”

Email: scliarov@yandex.ru

Leading Researcher

Russian Federation, Moscow

N. A. Litvinov

Federal State Institution “The Russian State Center for Quality and Standardization of Animal Drugs and Feed”

Email: scliarov@yandex.ru

Leading Specialist

Russian Federation, Moscow

References

  1. Berezovskaya I.V. Klassifikaciya himicheskih veshchestv po parametram ostroj toksichnosti pri parenteral’nyh sposobah vvedeniya // Himiko-farmacevticheskij zhurnal. 2003. T. 37. № 3. S. 32–34.
  2. Vahrusheva T.I. Analiz zabolevaemosti molodnyaka krupnogo skota vnutrennimi nezaraznymi patologiyami v AO PZ «Krasnoturanskij» Krasnoyarskogo kraya // V sb. Vseros. nauch. konf. g. Novosibirsk: IC INGAU «Zolotoj Kolos», 2019. S. 194–197.
  3. GOST 12.1.007-76. Mezhgosudarstvennyj standart. Sistema standartov bezopasnosti truda. Vrednye veshchestva. Klassifikaciya i obshchie trebovaniya bezopasnosti. Data vvedeniya 01.01.1977.
  4. GOST 33216-2014 «Rukovodstvo po soderzhaniyu i uhodu za laboratornymi zhivotnymi»
  5. Kondrahin I.P., Talanov G.A., Pak V.V. Vnutrennie nezaraznye bolezni zhivotnyh. M.: KolosS, 2003. 461 s.
  6. Pavlov D.K. Zabolevaniya zheludochno-kishechnogo trakta u novorozhdennyh telyat // Veterinarnaya zhizn’. 2006. № 11. S. 12–14.
  7. Rahmatullin E.K., Sklyarov O.D. Preparat dlya lecheniya i profilaktiki ostryh zheludochno-kishechnyh boleznej novorozhdennyh telyat. Patent na izobretenie 2740602 C1, 15.01.2021. Zayavka № 2020107209 ot 17.02.2020.
  8. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Chast’ pervaya. Pod obshchej redakciej doktora medicinskih nauk A.N. Mironova. M.: Grif i K, 2012. 944 s.
  9. Smolencev S.Yu. Metody lecheniya rasstrojstva pishchevareniya telyat (obzor) // Vestnik Marijskogo gosudarstvennogo universiteta. Seriya “Sel’skohozyajstvennye nauki. Ekonomicheskie nauki”. 2022. T. 8. № 3. S. 280–287. https://doi.org/10.30914/2411-9687-2022-8-3-280-287
  10. Habriev R.U. Rukovodstvo po eksperimental’nomu i doklinicheskomu izucheniyu novyh farmakologicheskih veshchestv. 2-e izd., pererab. i dop. M.: OAO “Izdatel’stvo ‘Medicina’”, 2005. 832 s.
  11. Hodge H.C., Gosselin R.E., Smith R.P., Gleason M.N. Clinical Toxicology of Commercial Products // Acute Poisoning. 4th ed., Williams & Wilkins, Baltimore. 1975. 427 p.

Copyright (c) 2024 Russian Academy of Sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies